PM
LCTX icon

Pembroke Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Pembroke Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-25,000
Closed -$23K – 66
2018
Q4 		$23K Buy
+25,000
New +$38.3K ﹤0.01% 57

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Pembroke Management's LCTX Position: Q1 2019 in Review

Pembroke Management sold out of Lineage Cell Therapeutics (LCTX) in Q1 2019, closing a stake of 25,000 shares — an estimated $23K sold.

Pembroke Management first reported a position in LCTX in Q4 2018 and held it in 1 quarter. The position peaked at $23K in Q4 2018. 118 funds tracked by Wall St. Rank hold LCTX as of Q1 2019.

  • Pembroke Management reported no remaining Lineage Cell Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Pembroke Management sold 25,000 Lineage Cell Therapeutics shares in Q1 2019, an estimated $23K.
  • Pembroke Management first reported a position in Lineage Cell Therapeutics in Q4 2018 and held it in 1 quarter.
  • Pembroke Management's Lineage Cell Therapeutics position peaked at $23K in Q4 2018.
  • 118 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2019.

Based on Pembroke Management's 13F filing for Q1 2019, filed 12 Apr 2019.